---
title: "Samrat Pharmachem Ltd (530125) — Share Price, Financials & Analysis"
symbol: "530125"
company: "Samrat Pharmachem Ltd"
canonical: "https://tapetide.com/stocks/530125"
isin: "INE103E01016"
nse_symbol: "SAMRATPHARMACHEMLTD"
bse_code: "530125"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 71.35
generated_at: "2026-09-13T18:37:09.452Z"
---

# Samrat Pharmachem Ltd (530125)

Canonical page: https://tapetide.com/stocks/530125

## Company

- **NSE Symbol:** SAMRATPHARMACHEMLTD
- **BSE Code:** 530125
- **ISIN:** INE103E01016
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** samratpharmachem.com

## About

Incorporated in 1992, Samrat Pharmachem Ltd does manufacturing and selling of chemicals[1]

## Latest Price

## Key Fundamentals

Observed at 2026-09-11T04:53:21.578800Z.

- **Market Cap:** ₹71.35 Cr
- **Classification:** Microcap
- **P/E (reported):** -32.4
- **EPS (TTM):** ₹-7.15
- **EPS (reported):** ₹7
- **Book Value:** ₹220.67
- **Price to Book:** 1.05
- **Dividend Yield:** 0.43%
- **ROE:** -4.86%
- **ROCE:** -2.95%
- **Debt to Equity:** 0.16
- **Revenue (yearly):** ₹290.6 Cr
- **Net Income:** ₹-3.3 Cr
- **EBITDA:** ₹-1.3 Cr
- **52-Week High:** ₹333
- **52-Week Low:** ₹190
- **RSI (14):** 44.53

## Tapetide Score

- **Score:** 59 / 100
- **Score date:** 2026-09-04
- **Archetype:** Quality at a Reasonable Price
- **What it means:** Financial strength is not being paid for with a demanding multiple. The question worth asking is whether the quality is durable or reflects a good patch — check the consistency of returns over several years rather than the latest quarter.
- **Pillar profile:** Quality: Good · Valuation: Cheap · Momentum: Rising
- **Percentile:** 84.7 (of 4473 scored stocks)
- **Confidence:** 91%
- **Data coverage:** 81%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 36.15 | 9% |
| growth | 44.08 | 9% |
| momentum | 72.31 | 12% |
| ownership | 50 | 24% |
| quality | 60.11 | 22% |
| valuation | 71.43 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Stock is trading at 1.03 times its book value

### Weaknesses

- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 10.1% over past five years.
- Company has a low return on equity of 2.15% over last 3 years.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 188.01% | -5.63% | -49.17% |
| ebitda margin growth | 226.67% | -111.51% | -133.09% | -104.03% |
| net income growth | 145% | -146.48% | -250% | -119.19% |
| revenue growth | 13.01% | 1.32% | -2% | 10% |
| roce | — | -120.08% | -160.08% | 21.09% |
| roe | — | -149.04% | 2.79% | -113.24% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 79.74 | 61.67 | 82.68 | 80.82 | 70.17 | 63.66 | 71.2 | 75.65 | 78.87 | 63.43 | 71.77 | 79.76 |
| Expenses | 79.51 | 61.56 | 81.32 | 78.24 | 66.8 | 59.48 | 71.07 | 75.52 | 79.23 | 64.08 | 73.01 | 78.87 |
| Operating Profit | 0.23 | 0.11 | 1.36 | 2.58 | 3.37 | 4.18 | 0.13 | 0.13 | -0.36 | -0.65 | -1.24 | 0.89 |
| OPM % | 0.29 | 0.18 | 1.64 | 3.19 | 4.8 | 6.57 | 0.18 | 0.17 | -0.46 | -1.02 | -1.73 | 1.12 |
| Other Income | 0.3 | 0.42 | 0.3 | 0.59 | 0.49 | 0 | -0.11 | 0.69 | 0.05 | 0.4 | -0.31 | 0.99 |
| Interest | 0.13 | 0.23 | 0.11 | 0.19 | 0.17 | 0.1 | 0.22 | 0.44 | 0.26 | 0.13 | 0.14 | 0.11 |
| Depreciation | 0.16 | 0.16 | 0.16 | 0.16 | 0.17 | 0.17 | 0.16 | 0.17 | 0.18 | 0.19 | 0.19 | 0.19 |
| Profit before tax | 0.24 | 0.14 | 1.39 | 2.82 | 3.52 | 3.91 | -0.36 | 0.21 | -0.75 | -0.57 | -1.88 | 1.58 |
| Tax % | 175 | -142.86 | 0 | 26.6 | 24.43 | 28.9 | 11.11 | 209.52 | -21.33 | -19.3 | 8.51 | 44.94 |
| Net Profit | -0.19 | 0.34 | 1.4 | 2.07 | 2.66 | 2.78 | -0.4 | -0.23 | -0.59 | -0.46 | -2.04 | 0.88 |
| EPS in Rs | -0.61 | 1.1 | 4.53 | 6.7 | 8.61 | 9 | -1.29 | -0.74 | -1.91 | -1.49 | -6.6 | 2.85 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 93 | 111 | 137 | 179 | 222 | 311 | 282 | 286 | 290 | 294 |
| Expenses | 87 | 108 | 131 | 170 | 197 | 287 | 279 | 276 | 292 | 295 |
| Operating Profit | 6 | 3 | 7 | 9 | 24 | 24 | 2 | 10 | -2 | -1 |
| OPM % | 6 | 2.9 | 4.8 | 4.8 | 11 | 8 | 0.9 | 3.6 | -0.7 | -0.5 |
| Other Income | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 5 | 2 | 6 | 7 | 24 | 23 | 3 | 10 | -3 | -2 |
| Tax % | 35 | 29 | 27 | 27 | 27 | 26 | 14 | 28 | 11 | — |
| Net Profit | 3 | 2 | 4 | 5 | 17 | 17 | 2 | 7 | -3 | -2 |
| EPS in Rs | 10.42 | 4.98 | 13.72 | 17.25 | 55.6 | 53.82 | 6.99 | 23.01 | -10.71 | -7.15 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 2 | 2 | 14 | 4 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves | 12 | 15 | 17 | 21 | 27 | 44 | 60 | 62 | 69 | 65 |
| Borrowings | 7 | 9 | 7 | 9 | 9 | 8 | 19 | 8 | 10 | 11 |
| Other Liabilities | 14 | 13 | 14 | 25 | 19 | 30 | 35 | 48 | 40 | 46 |
| Total Liabilities | 36 | 41 | 40 | 58 | 57 | 85 | 117 | 122 | 122 | 124 |
| Fixed Assets | 7 | 7 | 7 | 7 | 9 | 10 | 11 | 11 | 10 | 12 |
| CWIP | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 4 | 4 |
| Other Assets | 29 | 34 | 33 | 50 | 48 | 75 | 104 | 108 | 107 | 108 |
| Total Assets | 36 | 41 | 40 | 58 | 57 | 85 | 117 | 122 | 122 | 124 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | -3 | 0 | 2 | -1 | 5 | 17 | -9 | 9 | -10 | 9 |
| Cash from Investing Activity | 1 | -2 | 2 | -2 | -3 | -1 | -3 | 0 | 0 | -3 |
| Cash from Financing Activity | 1 | 2 | -4 | 2 | -2 | -2 | 10 | -11 | 0 | 0 |
| Net Cash Flow | -1 | -1 | 1 | -1 | 0 | 14 | -3 | -2 | -10 | 6 |
| Free Cash Flow | -4 | 0 | 2 | -3 | 3 | 16 | -11 | 9 | -11 | 6 |
| CFO/OP | -73 | 17 | 126 | -7 | 81 | 78 | 0 | 503 | -84 | -493 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 59 | 86 | 69 | 74 | 67 | 72 | 61 | 90 | 72 | 64 |
| Inventory Days | 41 | 31 | 28 | 55 | 25 | 24 | 43 | 28 | 52 | 56 |
| Days Payable | 43 | 46 | 45 | 67 | 39 | 45 | 42 | 65 | 53 | 55 |
| Cash Conversion Cycle | 58 | 70 | 52 | 61 | 53 | 51 | 62 | 53 | 71 | 65 |
| Working Capital Days | 34 | 32 | 37 | 39 | 36 | 32 | 40 | 47 | 68 | 52 |
| ROCE % | 16 | 23 | 12 | 22 | 24 | 52 | 35 | 3 | 13 | -3 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 48.64% | 48.64% | 48.64% | 48.64% | 48.95% | 49.09% | 49.09% | 49.09% | 49.09% | 49.09% | 49.09% | 49.09% |
| FIIs | 3.24% | 3.24% | 3.24% | 3.24% | 3.24% | 3.24% | 3.24% | 0% | 3.24% | 3.24% | 3.24% | 3.24% |
| DIIs | 0% | 0% | 0.22% | 0.22% | 0.22% | 0% | 0% | 3.24% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 42.58% | 42.61% | 41.69% | 40.79% | 41.34% | 41.95% | 41.58% | 41.64% | 41.73% | 41.5% | 41.75% | 41.51% |
| Others | 5.54% | 5.51% | 6.22% | 7.11% | 6.25% | 5.72% | 6.09% | 6.04% | 5.95% | 6.17% | 5.93% | 6.16% |
| No. of Shareholders | 8445 | 8065 | 7478 | 7169 | 6984 | 6844 | 6785 | 6752 | 6699 | 6488 | 6311 | 6330 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 2 / 6 / 11

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 231.95 | Sell |
| EMA (10) | 231.97 | Sell |
| SMA (20) | 235.65 | Sell |
| EMA (20) | 235.12 | Sell |
| SMA (50) | 245.11 | Sell |
| EMA (50) | 236.56 | Sell |
| SMA (100) | 229.48 | Sell |
| EMA (100) | 233.97 | Sell |
| SMA (200) | 225.96 | Buy |
| EMA (200) | 243.35 | Sell |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 41.73 | Neutral |
| MACD (12,26,9) | -3.51 | Sell |
| Stochastic (14,3,3) | 26.6 | Neutral |
| ADX (14) | 13.57 | Neutral |
| Williams %R (14) | -78.53 | Neutral |
| ATR (14) | 11.34 | High Volatility |
| ROC (12) | -6.58 | Sell |
| Stoch RSI (14) | 13.69 | Buy |
| UO (7,14,28) | 56.9 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-02 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=617b3282-ec8e-42e9-b0d4-ae2b209fece3.pdf) |
| 2026-08-27 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=edb99e77-4026-476f-829d-5f5a67f2cf6c.pdf) |
| 2026-08-27 | [34Th Annual General Meeting Of Samrat Pharmachem Limited To Be Held On Wednesday September 23 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=063ef7d3-4a87-4565-bbf9-d6a32e494185.pdf) |
| 2026-08-27 | [Book Closure: Sunday September 20 2026 To Tuesday September 22 2026 (Both Days Inclusive)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e3c3aaf8-5c97-45bd-bc73-a6cc40ec0ba2.pdf) |
| 2026-08-19 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1ec6acf6-5f06-4000-81ba-c3286104afd6.pdf) |
| 2026-08-14 | [Board Meeting Outcome for Outcome Of The Board Meeting Of The Company Held Today](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2aa033d1-4340-4f62-9071-02100eb337e9.pdf) |
| 2026-07-17 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fdb74ca9-44cc-440b-9fe2-af83ebfda129.pdf) |
| 2026-07-17 | [Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a61c9262-cde3-462d-86c6-dc2a14717bbf.pdf) |
| 2026-06-30 | [Board Meeting Intimation for Notice Of Board Meeting For Un-Audited Financial Results For The Quarter Ended June 30 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a6d28683-8ceb-4f87-8e7b-0350e67a9399.pdf) |
| 2026-06-29 | [Closure of Trading Window](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0f760085-fc79-48e0-b7a7-a9e1a3556689.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-05-30 | [Audited Financial Results For The Quarter And Year Ended 31 March 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=46f81cda-6802-4a1d-9dd1-42ae9ce0639c.pdf) |
| 2026-02-13 | [Un-Audited Financial Results For The Quarter Ended December 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5e0c0a85-911f-4161-868a-3c9f9cdb7fa2.pdf) |
| 2025-11-14 | [Un-Audited Financial Results For The Quarter And Half Year Ended 30Th September 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=96836303-5b85-44d0-8414-bcfccc261935.pdf) |
| 2025-08-13 | [Un-Audited Financial Results For The Quarter Ended June 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=513c53ad-7395-4cdf-8c6c-8851869bff43.pdf) |
| 2025-05-30 | [Audited Financial Results For The Year Ended March 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b7dd076a-1193-4455-9d6c-55970a1a78cb.pdf) |
| 2025-02-14 | [Approval Of Un-Audited Financial Results For The Quarter Ended December 31 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e6770c60-2783-454d-a588-020d3e4dc3a8.pdf) |
| 2024-11-14 | [Un-Audited Financial Results For The Quarter Ended September 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bc448e85-c201-4689-988a-e8e670244bed.pdf) |
| 2024-08-13 | [Un-Audited Financial Results For The Quarter Ended June 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ccb381ae-1c62-4d57-b0c6-ddafd424462d.pdf) |
| 2024-05-30 | [Audited Financial Results For The Year Ended March 31, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2c54931d-43e8-44f8-aa2c-8ba0964a30c5.pdf) |
| 2024-02-14 | [Approval Of Unaudited Standalone Financial Results For The Quarter Ended December 31, 2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b8882a8c-770d-42e4-99f0-9be467a83a9e.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9 Feb - Earnings transcript of Q3 & FY 26 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript 9 Feb - Earnings transcript of Q3 & FY 26](https://www.bseindia.com/xml-data/corpfiling/AttachHis/caa85d9e-4f24-4fdd-a3a9-050be3ff4b2d.pdf) |
| 7 Apr - Samrat Pharmachem confirms it is not a Large Corporate under SEBI criteria. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 7 Apr - Samrat Pharmachem confirms it is not a Large Corporate under SEBI criteria.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c89d1c79-f58c-4de8-93bf-c4321293b1ba.pdf) |
| 7 Apr - Certificate u/r 74(5) for the quarter ended March 31, 2026 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 7 Apr - Certificate u/r 74(5) for the quarter ended March 31, 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2ad9d3e0-cf00-480a-b9ca-c386ac9fa60a.pdf) |
| 6 Feb - Newspaper advertisement of dec 2025 Results | [Announcement under Regulation 30 (LODR)-Newspaper Publication 6 Feb - Newspaper advertisement of dec 2025 Results](https://www.bseindia.com/xml-data/corpfiling/AttachHis/deb93395-7f58-4655-bcb8-648509237865.pdf) |
| 6 Feb - Earnings call audio for quarter and nine months ended Dec 31, 2025 posted on company website (06-Feb-2026). | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 6 Feb - Earnings call audio for quarter and nine months ended Dec 31, 2025 posted on company website (06-Feb-2026).](https://www.bseindia.com/xml-data/corpfiling/AttachHis/750cfe14-3501-4f70-a577-18cd1c85c70e.pdf) |
| 6 Feb - CRISIL monitoring report: IPO proceeds Rs1,353.40m utilization, Rs422.23m unutilized, quarter ended Dec 31, 2025. | [Announcement under Regulation 30 (LODR)-Monitoring Agency Report 6 Feb - CRISIL monitoring report: IPO proceeds Rs1,353.40m utilization, Rs422.23m unutilized, quarter ended Dec 31, 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a365c750-b065-4c8f-b9ab-eca7f4bdb107.pdf) |
| 30 Mar - Crisil revised Samrat Pharmachem bank facilities rating to BB/Stable/A4+ from BB+/Negative/A4+ on March 30, 2026. | [Announcement under Regulation 30 (LODR)-Credit Rating 30 Mar - Crisil revised Samrat Pharmachem bank facilities rating to BB/Stable/A4+ from BB+/Negative/A4+ on March 30, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/49eb3a58-03d2-4ead-96db-f1e89d1bfa08.pdf) |
| 29 Dec 2025 - Trading window closed Jan 1, 2026 until 48 hours after unaudited results for quarter ended Dec 31, 2025. | [Closure of Trading Window 29 Dec 2025 - Trading window closed Jan 1, 2026 until 48 hours after unaudited results for quarter ended Dec 31, 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5a2b30e7-9b38-4d22-a23b-6b743cb86cc1.pdf) |
| 29 Dec 2025 - Board meeting on 13-Feb-2026 to consider Un-Audited results for quarter ended 31-Dec-2025. | [Board Meeting Intimation for Un-Audited Financial Results For The Quarter Ended December 31, 2025 29 Dec 2025 - Board meeting on 13-Feb-2026 to consider Un-Audited results for quarter ended 31-Dec-2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7e3cf265-9621-4976-833a-44baba1d434e.pdf) |
| 25 Mar - Board meeting on May 30, 2026 to approve audited standalone results for year ended March 31, 2026. | [Board Meeting Intimation for Audited Financial Results For The Financial Year Ended March 31, 2026 25 Mar - Board meeting on May 30, 2026 to approve audited standalone results for year ended March 31, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b97771af-19fd-4641-a872-fe50735f4273.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Sep 2025 | [Concall - Sep 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d0124dc3-6c4c-4450-be30-1e60b99219ce.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e77a2cdc-f770-4c9f-95cb-0f9c8aa0bc16.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a8f19517-abf3-4bc8-b37c-9adf7c6219fa.pdf) |
| May 2025 | [Concall - May 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3fe9e3d3-23bc-4c72-a7b6-6ca05931c879.pdf) |
| Mar 2025 | [Concall - Mar 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0e57ab71-256b-474e-b422-225ce2a0d96d.pdf) |
| Mar 2025 | [Concall - Mar 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/72ccb207-fea6-4cf0-b5d4-3482b25c9d5e.pdf) |
| Jun 2025 | [Concall - Jun 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e815226a-51f3-4ef4-80c0-06bd2a510f8c.pdf) |
| Feb 2025 | [Concall - Feb 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/72940897-aecc-4ea9-b46e-7c0025493ab1.pdf) |
| Aug 2025 | [Concall - Aug 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/444ad236-3ec5-4d7f-be50-481ede550237.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ab973ccf-f6e4-48fc-b834-d4c05839e3e3.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9cc3ab47-40fc-4c42-8f16-e19aa01478f2.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6c0f7e7b-920b-4dea-87b1-79a379536da0.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d7142dc3-a77e-48ba-8289-a7f8156230e4.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/530125/75424530125.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/530125/71531530125.pdf) |
| from bse | [Annual Report 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/530125/67833530125.pdf) |
| from bse | [Annual Report 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/530125/5301250319.pdf) |
| from bse | [Annual Report 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/530125/5301250318.pdf) |
| from bse | [Annual Report 2017 from bse](https://www.bseindia.com/bseplus/AnnualReport/530125/5301250317.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:37:09.452Z.